Results 101 to 110 of about 19,899 (238)

FX2149 reduced LRRK2 phosphorylation.

, 2015
A and B. HEK293T cells were transiently transfected with Flag tagged G2019S-LRRK2 construct for 36 h and then starved with no serum media for 12 hours. Then vehicle, FX2151 (10 μM, a non-effective analog of 68), or FX2149 (10 and 100 nM) were treated for
Shijun Zhong (713594), Wanli W. Smith (564031), Tianxia Li (564028), Xinhua He (291623), Joseph M. Thomas (713593), Fengtian Xue (713595), Dejun Yang (564027)   +6 more
core   +1 more source

The Effect of LRRK2 and GBA1 Mutations on Survival in Early‐ and Late‐Onset Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Mutations in the glucocerebrosidase 1 (GBA1) and leucine‐rich repeat kinase 2 (LRRK2) genes are associated with Parkinson's disease (PD) phenotype. Objective To asses the contribution of genetic status to long‐term survival of patients with PD.
Raz Rubin, Roy N. Alcalay, Nurit Omer, Orly Goldstein, Mali Gana Weisz, Anat Mirelman, Avner Thaler   +6 more
wiley   +1 more source

An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S Cohorts

Journal of Parkinson’s Disease, 2020
The phosphorylated form of LRRK2, pS935 LRRK2, has been proposed as a target modulation biomarker for LRRK2 inhibitors. The primary aim of the study was to characterize and qualify this biomarker for therapeutic trials of LRRK2 inhibitors in Parkinson’s ...
Shalini Padmanabhan, Thomas A. Lanz, Donal Gorman, Michele Wolfe, Alison Joyce, Carlos Cabrera, Rosemary Lawrence-Henderson, Najah Levers, Neal Joshi, Thong C. Ma, Christopher Liong, Sushma Narayan, Roy N. Alcalay, Samantha J. Hutten, Marco A.S. Baptista, Kalpana Merchant   +15 more
doaj   +1 more source

Integrative Multi‐Omics Analysis Reveals Convergent Epigenome and Transcriptome Changes in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background The mechanisms that predispose dopaminergic neurons (DAN) to degeneration in Parkinson's disease (PD) are incompletely understood. Objective To perform an integrative multi‐omics reanalysis of single‐cell transcriptomic and epigenomic data to identify convergent alterations predisposing dopaminergic neurons to degeneration in ...
Mirco Macchi, Aurélien Ginolhac, Tony Heurtaux, Borja Gomez‐Ramos, Lasse Sinkkonen, Enrico Glaab, on behalf of the NCER‐PD Consortium, Mariella Graziano, Alexandre Bisdorff, Rene Dondelinger, Elodie Thiry, Gelani Zelimkhanov, Guy Berchem, Liliana Vilas Boas, Linda Hansen, Martine Goergen, Nancy De Bremaeker, Nico Diederich, Romain Nati, Roxane Batutu, Sylvia Herbrink, Jochen Klucken, Rejko Krüger, Claire Pauly, Lukas Pavelka, Marijus Giraitis, Maria Fernanda Niño Uribe, Achilleas Pexaras, Alexander Hundt, Alexia Mendibide, Ana Festas Lopes, Angelo Ferrari, Brian Dewitt, Carlos Gamio, Estelle Henry, Gaël Hamot, Geeta Acharya, Hermann Thien, Ilsé Richard, Johanna Trouet, Kate Sokolowska, Katy Beaumont, Laura Georges, Lorieza Castillo, Lucie Remark, Maeva Munsch, Margaux Henry, Maud Theresine, Olga Kofanova, Olivia Roland, Pauline Lambert, Saïda Mtimet, Wim Ammerlaan, Anne Grünewald, Armin Rauschenberger, Clarissa P.C. Gomes, Dheeraj Reddy Bobbili, Ekaterina Soboleva, Elisa Gómez de Lope, Enrico Glaab, Evi Wollscheid‐Lengeling, Francoise Meisch, Giuseppe Arena, Ibrahim Boussaad, Iñigo Yoldi Bergua, Jens Schwamborn, Kirsten Roomp, Laure Pauly, Michael T. Heneka, Michele Bassis, Muhammad Ali, Jade Jaber, Patricia Martins Conde, Patrick May, Paul Wilmes, Piotr Gawron, Rebecca Ting Jiin Loo, Reinhard Schneider, Ruxandra Soare, Sabine Schmitz, Sarah Nickels, Sascha Herzinger, Sinthuja Pachchek, Soumyabrata Ghosh, Stefano Sapienza, Valentin Groues, Venkata Satagopam, Isabel Schwaninger, Liyousew Borga, Sijmen Van Schagen, Gabriel Martinez Tirado, Alan Castro Mejia, Messaline Fomo, Niloofar Kheradbin, Francesca Boschi, Francesca Terranova, Jochen Ohnmacht, Anne‐Marie Hanff, Carlos Vega, Chouaib Mediouni, Deborah Mcintyre, Eduardo Rosales, Fozia Noor, Gessica Contesotto, Gloria Aguayo, Guilherme Marques, Jérôme Graas, Joëlle Fritz, Magali Perquin, Manon Gantenbein, Maura Minelli, Michel Vaillant, Myriam Alexandre, Myriam Menster, Olena Tsurkalenko, Raquel Severino, Sibylle Béchet, Tainá M. Marques, Ulf Nehrbass, Victoria Lorentz, Zied Landoulsi, Sonja Jónsdóttir, David Bouvier, Katrin Frauenknecht, Michel Mittelbronn, Roseline Lentz, Jean‐Paul Nicolay, Nadine Jacoby   +127 more
wiley   +1 more source

An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2

Neurobiology of Disease, 2019
Background: Mutations in LRRK2 are the most common cause of autosomal dominant Parkinson's disease, and the relevance of LRRK2 to the sporadic form of the disease is becoming ever more apparent.
Natalie Connor-Robson, Heather Booth, Jeffrey G. Martin, Benbo Gao, Kejie Li, Natalie Doig, Jane Vowles, Cathy Browne, Laura Klinger, Peter Juhasz, Christine Klein, Sally A. Cowley, Paul Bolam, Warren Hirst, Richard Wade-Martins   +14 more
doaj   +1 more source

Dopamine‐Deficiency‐Related Reorganization of the Somatomotor Network in Prodromal and Early Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Introduction Network attack tolerance (NAT) measures the brain's ability to sustain information flow despite the loss of critical brain regions. In Parkinson's disease (PD), NAT has been linked to cognitive and motor function. However, it remains unclear how dopaminergic degeneration shapes NAT, and whether it relates to motor symptom ...
Adrian L. Asendorf, Verena Dzialas, Thilo van Eimeren, Merle C. Hoenig   +3 more
wiley   +1 more source

What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson’s Disease Patients and Healthy Subjects with Parkinson’s-Associated LRRK2 Mutations?

Journal of Parkinson’s Disease, 2019
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common known cause of autosomal dominant Parkinson’s disease (PD) and sporadic PD (sPD).
David A. Loeffler, Jan O. Aasly, Peter A. LeWitt, Mary P. Coffey   +3 more
doaj   +1 more source

PREDICT‐PD: A Two‐Stage Approach to Early Identification of Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Sasivimol Virameteekul, Sheena Waters, Brook Huxford, Ashvin Kuri, Manuela Tan, Laura Pérez‐Carbonell, Eduardo de Pablo‐Fernández, Anette Schrag, Alastair J. Noyce, Cristina Simonet   +9 more
wiley   +1 more source

Ursodeoxycholic Acid and Parkinson's Disease Risk: An Emulated Target Trial in UK Electronic Health Records

Movement Disorders, EarlyView.
Abstract Background Ursodeoxycholic acid (UDCA) has shown mitochondrial and neuroprotective effects and has been proposed as a treatment for Parkinson's disease (PD). However, population‐level evidence on its effect on PD risk is lacking. Objectives To compare the risk of incident PD among UDCA initiators versus matched non‐initiators within a ...
Chengsheng Ju, Anette Schrag, Camille Carroll, Xi Xiong, James Carpenter, Oliver Bandmann, Thomas Foltynie, Li Wei   +7 more
wiley   +1 more source

Lrrk2 Pathogenic Substitutions in Parkinson's Disease

, 2009
Leucine-rich repeat kinase 2 (LRRK2) mutations have been implicated in autosomal dominant parkinsonism, consistent with typical levodopa-responsive Parkinson's disease. The gene maps to chromosome 12q12 and encodes a large, multifunctional protein.
Mata, Ignacio F.; Kachergus, Jennifer M.; Taylor, Julie P.; Lincoln, Sarah; Aasly, Jan; Lynch, Timothy; Hulihan, Mary M.; Cobb, Stephanie A.; Wu, Ruey-Meei; Lu, Chin-Song; Lahoz, Carlos; Wszolek, Zbigniew K.; Farrer, Matthew J., 吳瑞美;陸清松   +1 more
core